ArticleIOSR journal of dental and medical sciences2025
Investigating Anti-Breast Cancer Properties of the Antibiotic Vancomycin-A Drug Repurposing study using
Article in IOSR journal of dental and medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The incidence of triple-negative breast cancer (TNBC) is approximately 10-15% of all breast cancer cases around the world. It is important to search for novel therapeutic agents against TNBC since this form of cancer is a leading cause of death in women worldwide. Various genetic mutations in TNBC patients have been identified. EZH2 is an oncoprotein involved in breast, prostate, colon, and other cancers. In silico drug design and bioinformatics studies helped to identify the FDA approved antibiotic, vancomycin as a potential inhibitor of the EZH2 oncoprotein. A drug repurposing study of vancomycin to investigate the potential anti TNBC properties was tested by doing cytotoxicity analysis with vancomycin in TNBC cell lines by WST-8 assay, spheroid forming assay and ROS generation experiments. The EZH2 inhibitor property of vancomycin was studied by RT-PCR and ELISA assay. Our initial results showed that Vancomycin effectively prevents cell proliferation, spheroid formation and generates ROS in the TNBC cell lines tested as well as inhibit the EZH2 gene expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.